Share
Big tech is transforming every aspect of our world. But how, and at what cost? This season of Land of the Giants – The Disney Dilemma – focuses on Disney’s ability to weather the ups and downs of the business cycle and changing tastes and explores what has kept it successful for over 100 years. The entertainment giant has leveraged nostalgia and its intellectual property to build a beloved brand, but after an acquisition spree that included Marvel, Lucasfilm, and 20th Century Fox, can it sus ...
…
continue reading
Reimagining Gene and Cell Therapy: Helen Sabzevari on Precigen’s Breakthroughs in Precision Medicine
Manage episode 492947012 series 1551347
Content provided by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company’s cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen’s unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen’s broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland’s BioHealth Capital Region has supported the company’s innovation and growth.
Editing and post-production work for this episode was provided by The Podcast Consultant.
Dr. Helen Sabzevari is the President and CEO of Precigen, Inc., and a leading expert in immunotherapy-based therapeutics. She previously served in executive roles at Compass Therapeutics and Merck KGaA/EMD Serono, where she advanced numerous immuno-oncology programs. Dr. Sabzevari began her career at the National Cancer Institute and has been widely recognized for her leadership and scientific contributions, including honors from NIH, SITC, and Forbes.
181 episodes
))
